ClinicalTrials.Veeva

Menu

Tissue Procurement Substudy for Participants in Study CP-MGA271-01

MacroGenics logo

MacroGenics

Status and phase

Terminated
Phase 1

Conditions

Melanoma

Treatments

Biological: MGA271

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01918930
CP-MGA271-01a

Details and patient eligibility

About

The purpose of this study is to gain a better understanding about how the study drug MGA271 works. No test drug will be given in this study. Patients with easily accessible tumors at the screening visit for participation in Study CP-MGA271-01 will be asked to participate in this substudy. Patients will undergo two excisional biopsies, punch biopsies, or core needle biopsies.

Full description

Patients with easily accessible tumors (generally, metastatic deposits involving skin, subcutaneous tissues, or peripheral lymph node whose excision would not require general anaesthesia or the invasion of a body cavity) at the screening visit for participation in Study CP-MGA271-01 (the main study) will be asked to participate in this substudy. After providing appropriate informed consent, patients will undergo excisional biopsy, punch biopsy, or core needle biopsy of the accessible tumor prior to receiving study drug in the main study and then again after the first cycle of study drug is completed.

Some of the biopsy tissue will be sent to a central laboratory for research purposes. The central lab will analyze the tissue to see what effects that the study drug might have on tumors.

Enrollment

6 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Qualified, by meeting all inclusion and exclusion criteria, for participation in Study CP-MGA271-01.
  • Must have provided informed consent to participate in Study CP-MGA271-01.
  • Must have accessible tumors (generally speaking, metastatic deposits involving skin, subcutaneous tissue, or peripheral lymph node whose excision, punch biopsy, or core needle biopsy would not require general anaesthesia or the invasion of a body cavity).
  • Willing to undergo two minor surgical procedures with no expectation of personal benefit
  • Have provided Informed Consent for this substudy as indicated by a signature on an approved consent document obtained from the patient or his/her legally authorized representative

Exclusion criteria

  • Any medical condition that would contraindicate the use of local or locoregional anaesthesia, or conscious sedation for the intended minor surgical procedure.
  • Any medical condition (eg. skin disease or bleeding diathesis) that would hinder wound healing following a minor surgical procedure.
  • Dementia or altered mental status that would preclude understanding and rendering of informed consent.

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

6 participants in 1 patient group

MGA271
Experimental group
Description:
MGA271 (administered in main study CP-MGA271-01)
Treatment:
Biological: MGA271

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems